论文部分内容阅读
目的探讨并分析埃滋蛋白(Ezrin)和核纤层蛋白A/C抗体(Lamin A/C)在卵巢癌组织中的表达变化及其与患者临床病理特征的关系。方法选取2011年5月—2016年5月在湖北中医药大学黄家湖医院病理科收集的30例正常卵巢组织标本(正常组)、手术后切除经病理学证实的卵巢癌标本65例(卵巢癌组)及卵巢良性肿瘤组织40例(良性组),采用免疫组织化法检测3组标本中的Ezrin和Lamin A/C蛋白的表达情况,并分析其与患者的临床病理特征的关系。结果正常组、良性组的卵巢组织标本中Ezrin和Lamin A/C蛋白表达阳性率分别为93.33%、87.50%、93.33%、90.00%,显著高于卵巢癌组的49.23%、52.31%,差异均有统计学意义(P<0.05);卵巢组织标本中Ⅰ+Ⅱ期、高+中分化、未发生淋巴结转移的患者Ezrin和Lamin A/C蛋白表达阳性率显著高于Ⅲ+Ⅳ期、低分化、发生淋巴结转移的卵巢癌患者,差异均有统计学意义(P<0.05)。结论 Ezrin和Lamin A/C蛋白的表达与卵巢癌转移密切相关,Ezrin和Lamin A/C蛋白在卵巢癌组织中表达下调,并且与患者的临床病理特征具有一定的关系,同时提示了Lamin A/C以及Ezrin可以作为潜在的卵巢癌患者病情评估以及临床预后的指标。
Objective To investigate and analyze the expression of Ezrin and Lamin A / C in ovarian cancer and its relationship with clinicopathological features. Methods Thirty normal ovarian tissues (normal group) collected from May 2011 to May 2016 in Huangjiahu Hospital of Hubei University of Traditional Chinese Medicine were collected. Totally 65 ovarian cancer specimens (ovarian cancer group ) And benign ovarian tumors (benign group). The expression of Ezrin and Lamin A / C in three groups of specimens was detected by immunohistochemistry and the relationship between them was analyzed with the clinicopathological features of the patients. Results The positive rates of Ezrin and Lamin A / C in normal and benign groups were 93.33%, 87.50%, 93.33% and 90.00%, respectively, which were significantly higher than those in ovarian cancer group (49.23% and 52.31%, respectively) (P <0.05). The positive rates of Ezrin and Lamin A / C protein expression in stage Ⅰ + Ⅱ, stage Ⅰ + stage Ⅱ, stage Ⅰ + stage Ⅱ, and stage Ⅱ + stage lymph node metastasis in ovarian tissue specimens were significantly higher than those in stage Ⅲ + , Lymph node metastasis in patients with ovarian cancer, the difference was statistically significant (P <0.05). Conclusions The expression of Ezrin and Lamin A / C protein is closely related to the metastasis of ovarian cancer. The expression of Ezrin and Lamin A / C protein is down-regulated in ovarian cancer and has some relationship with the clinicopathological features of the patients. Meanwhile, it is suggested that Lamin A / C and Ezrin can be used as potential indicators of disease progression and prognosis in patients with ovarian cancer.